Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14262
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Letter: Immunogenicity of Anti-TNF in Elderly IBD Patients

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Editorial: Antigenic Response to CT-P13 and Infliximab Originator in IBD Shows Similar Epitope Recognition-Evidence From Basic Science Supports Safe Switching to Biosimilars. Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Letter: Immunogenicity of Anti-TNF in Elderly IBD Patients-Authors' Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

PWE-102 Infective Diarrhoea Complicating Ibd vs Non-Ibd Patients

Gut
Gastroenterology
2014English

Editorial: CT-P13, a Biosimilar of Anti-Tumour Necrosis Factor-Alpha Agent (Infliximab), in Inflammatory Bowel Diseases

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Letter: New Thresholds Need to Be Defined When Using Point of Care Assays to Monitor Infliximab Trough Levels in IBD Patients

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Budget Impact Analysis of Biosimilar Infliximab (CT-P13) for the Treatment of Rheumatoid Arthritis in Six Central and Eastern European Countries

European Journal of Health Economics
Health PolicyEconomicsEconometricsFinance
2014English

THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy